Trifarma Spa, based in Italy, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is TRANYLCYPROMINE SULFATE, with a corresponding US DMF Number 16522.
Remarkably, this DMF maintains an Active status since its submission on February 27, 2003, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of May 17, 2019, and payment made on May 13, 2019, indicating their dedication to facilitating drug approvals, Categorized as Type II